Thursday, August 08, 2024 5:15:12 PM
Investor082,
First of all it’s possible to likely that not every big pharma is a welcome partner. Seems to me that Merck was vetted since Dr. Duffy was brought in to help but what about the rest? Mr. Cofer Black is on the board for a good reason and if you have not figured out by now that NWBO can be considered a threat to future big pharma profits then shared due diligence to this point by many longs has just been ignored by you. I believe you make too many assumptions about partnership timing although I agree with you that a partnership deal might be announced after a MHRA approval just because the need to do so can’t be kept secret forever. Partnerships now are not likely going to be inked on terms that big pharma wants. Anykne thinking so should have figured this out by now. Big pharma waited too long to get real and now they are just holding on to what they have for as long as possible before deals are made. Deals will be made because of THEIR NEED to stay relevant in light of possible threats from generic competition not only directly but also for combo scenarios with L before Direct takes center stage. These threats will be coming right when Flaskworks is powering up. See the issue big pharma reliance on checkpoint inhibitor profits has created as the patent cliff approaches and their attempts to move to a new patent protected administration method has created a greater risk of death. NWBO does and that puts them in the driver’s seat with negotiations. So will big pharma bite the bullet at approval or wait until Flaskworks to try and maximize current advantage as long as possible before funding for Direct trials becomes available? Some of the bears here want to project that the price won’t rise very much with approval. Gee, I wonder why; ). Best wishes.
First of all it’s possible to likely that not every big pharma is a welcome partner. Seems to me that Merck was vetted since Dr. Duffy was brought in to help but what about the rest? Mr. Cofer Black is on the board for a good reason and if you have not figured out by now that NWBO can be considered a threat to future big pharma profits then shared due diligence to this point by many longs has just been ignored by you. I believe you make too many assumptions about partnership timing although I agree with you that a partnership deal might be announced after a MHRA approval just because the need to do so can’t be kept secret forever. Partnerships now are not likely going to be inked on terms that big pharma wants. Anykne thinking so should have figured this out by now. Big pharma waited too long to get real and now they are just holding on to what they have for as long as possible before deals are made. Deals will be made because of THEIR NEED to stay relevant in light of possible threats from generic competition not only directly but also for combo scenarios with L before Direct takes center stage. These threats will be coming right when Flaskworks is powering up. See the issue big pharma reliance on checkpoint inhibitor profits has created as the patent cliff approaches and their attempts to move to a new patent protected administration method has created a greater risk of death. NWBO does and that puts them in the driver’s seat with negotiations. So will big pharma bite the bullet at approval or wait until Flaskworks to try and maximize current advantage as long as possible before funding for Direct trials becomes available? Some of the bears here want to project that the price won’t rise very much with approval. Gee, I wonder why; ). Best wishes.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
